Showing results (561-570 of 568) with videos related to
Sort By:
Pageof 57
You have reached the last page of results.This site can display upto 568 results.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology|May 19, 2024
Continuing benefits of the Montreal Protocol and protection of the stratospheric ozone layer for human health and the environmentS Madronich, G H Bernhard, P J Neale, et al.Cell|May 6, 2017
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and MexicoDavide F Robbiani, Leonia Bozzacco, Jennifer R Keeffe, et al.BMJ Open|March 20, 2023
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and SwedenLiv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, et al.Journal of Internal Medicine|February 15, 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trialG L Goll, K K Jørgensen, J Sexton, et al.Critical Care (London, England)|January 10, 2023
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, José R Arribas, Lambert Assoumou, et al.The Journal of Experimental Medicine|August 16, 2019
Risk of Zika microcephaly correlates with features of maternal antibodiesDavide F Robbiani, Priscilla C Olsen, Federico Costa, et al.Pageof 57